Harry L. Leider insider trades: Organicell Regenerative Medicine (OCEL) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Harry reports to the SEC
Open-market buys and sales
2 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Dec 19, 2023 | OCEL | ↓ Sell | 5,248 | $1.31 | $7K | Indirect | Dec 20, 2023 (1d) |
| Jun 29, 2023 | OCEL | ↑ Buy | 1,049,450 | $0.06 | $59K | Indirect | Jun 30, 2023 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Harry L. Leider's insider trades
Harry L. Leider is Chief Executive Officer at Organicell Regenerative Medicine (OCEL). Since Jun 29, 2023, Harry has reported 1 open-market purchase worth $59K and 1 sale worth $7K on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every OCEL insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.